Amitabh Chandra & Craig Garthwaite
What would indication-based drug pricing accomplish?
Henry Aaron, Matthew Fiedler, Paul B. Ginsburg, Loren Adler & Alice M. Rivlin
The threat to individual market stability is real. We need to fix it before it's too late.
Case Study by
Umesh Khot, Michael Militello & Eric Vogan
In the face of major pharmaceutical price increases, Cleveland Clinic developed a strategy to ensure high-quality patient care while maintaining financial stability.
K. John McConnell & Michael Chernew
Both political parties should support policies that focus on incentives as a mechanism for improving and sustaining their value.
Ashish K. Jha
Poor measures of care quality have consequences. The National Quality Forum is essential to creating measures that are valid and reliable.
The loss of CSR payments would create some short term chaos in the market, but it would not significantly impact the number of people covered.
Hoangmai Pham & Mark McClellan
Two veterans of public service say that government can do only so much — which creates attractive business opportunities for entrepreneurs.
Why can't EHRs talk to one another? We never created the right incentives, but we pretend that we did.
Allan H. Goroll
What's the effect of the mode of physician payment when it comes to EHRs?
Benson Hsu, Doug Nowak & Justin Smith
Centralizing clinical data for an integrated delivery system revealed a surprising lesson: sometimes predictive analytics are not enough.